Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Searle drops development of gpIIb/IIIa receptor antagonists

Jan. 25, 1999

Potent heterocyclic antithrombotic agents discovered by Lilly

Jan. 25, 1999

Integrin receptor antagonists, prodrugs and transdermal iontophoretic administration

Jan. 22, 1999

DuPont presents potent, orally active antiplatelet agent with good duration of action

Jan. 21, 1999

New market introduction for Organon's anticoagulant

Jan. 20, 1999

Oral heparin shown equivalent in efficacy and safety to injectable heparin

Jan. 19, 1999

Z-335 characterized as potent, orally effective and long-acting antiplatelet/antithrombotic agent

Jan. 19, 1999

Beraprost to enter clinical trials in North America

Jan. 18, 1999

FDA approves Pletal for intermittent claudication

Jan. 18, 1999

FDA approves home use of Lovenox in patients with potentially life-threatening blood clots

Jan. 8, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
HX-16108 holds promise for treating inflammatory skin diseases
BioWorld Science
Atopic dermatitis (AD) is an inflammatory skin disease accompanied by pruritus, for which IL-13 and IL-31 are clinically validated targets. Earendil Labs Inc. has...